All News
  • All News
  • In the News
  • Press Releases
  • Publications
  • Events
  • Video
  • Noteworthy Articles

SeptiCyte™ LAB Differentiates Sepsis from SIRS in the ICU

Design and results of clinical trials that led to FDA clearance of SeptiCyte™ LAB published in the American Journal of Respiratory and Clinical Care Medicine SEATTLE, May 9, 2018 /PRNewswire/ -- Immunexpress, Inc. today announced the publication in the American Journal of Respiratory and Clinical Care Medicine of the design and results of clinical trials...

Immunexpress Appoints Rolland Carlson, Ph.D., as Chief Executive Officer

Industry veteran brings a successful track record fundraising and launching commercial products Appointment strengthens the leadership team and positions the company for its targeted commercial launch   SEATTLE, April 10, 2018 – Immunexpress, Inc. today announced the appointment of Rolland D. Carlson, Ph.D., as chief executive officer, effective April 9,...

Validation of a Host Response Assay, SeptiCyte LAB, for Discriminating Sepsis from Systemic Inflammatory Response Syndrome in the ICU

Miller et al., American Journal of Respiratory and Critical Care Medicine | SeptiCyte LAB appears to be a promising diagnostic tool to complement physician assessment of infection likelihood in critically ill adult patients with systemic inflammation.
genome web

Biocartis Partnership May Enable Immunexpress to Move Sepsis Test to Point of Care

Biocartis Group NV (‘Biocartis’), an innovative molecular diagnostics company and Immunexpress have entered into a partnership agreement aimed at the development and commercialization of Immunexpress’ SeptiCypte™ test for use on Biocartis’ sample-to-result Idylla™ platform.

Brief-Biocartis & Immunexpress Partnership For A Sepsis Host Immune Response Test

Immunexpress and Biocartis enter an agreement to develop and commercialize SeptiCyte™ technology for use on sample-to-result Idylla™  platform.
genome web

Biocartis, Immunexpress Partner to Develop Sepsis Test

Biocartis and Immunexpress partner to develop a fully automated sepsis test, allowing for fast near-patient testing, resulting in potentially life-saving clinical information.

Biocartis, Immunexpress Partner to Develop Sepsis Test

Biocartis & Immunexpress sign partnership for a sepsis host immune response test on the Idylla™ platform.

Biocartis & Immunexpress Sign Partnership for a Sepsis Host Immune Response Test on the Idylla™ platform

Mechelen (Belgium)/Seattle (United States), 24 January 2018 – Biocartis Group NV (‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART) and Immunexpress Pty Ltd (‘Immunexpress’), a host response molecular diagnostic company, committed to improving clinical and economic outcomes for suspected sepsis patients, today announce that they have entered into a...
ISF Square

International Sepsis Forum 2017

International Sepsis Forum 2017 11-13 September, 2017 Paris, France Dr Leo McHugh presented an algorithmic method for interpreting the performance of high accuracy diagnostics when judged against clinical diagnoses known to contain uncertainty. This is the first public release of this method and associated open-course software for the diagnostics community....
news medical life science.

Differentiating sepsis and systemic inflammatory response syndrome using biomarkers

An interview with Dr. Richard Brandon, Chief Scientific Officer, Immunexpress, conducted by April Cashin-Garbutt, MA (Cantab).

A Four-Biomarker Blood Signature Discriminates Systemic Inflammation Due to Viral Infection Versus Other Etiologies

Sampson et al., Scientific Reports | Data demonstrates the ability of a four-biomarker blood signature to discriminate viral and non-viral causes of systemic inflammation in a variety of clinical settings. Discussed is the investigation of how to determine if a blood-based signature could be discovered and show a host systemic...

Four-Biomarker Signature Differentiates Viral and Non-Viral Causes of Systemic Inflammation

Results from an investigation of over 40 datasets published in Scientific Reports SEATTLE, June 6, 2017 /PRNewswire/ -- Immunexpress, Inc., a molecular diagnostic company with the first FDA cleared host response assay for suspected sepsis patients, today announced the publication, in Scientific Reports, of data demonstrating the ability of a four-biomarker...

If you are a member of the media, please contact:

Maggie Beller
Russo Partners
(646) 942-5631